contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforias-partner-network-expands-to-canada

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Analytiker

Frans-Mikael Rostedt

Aiforia Technologies utrustar patologer och forskare i prekliniska och kliniska laboratorier med programvara för att översätta bilder till upptäckter, beslut och diagnoser. Bolagets produkter och tjänster används för medicinsk bildanalys, över en mängd olika områden från onkologi till neurovetenskap. Aiforia Technologies har sitt huvudkontor i Finland.

Samma på svenska                    Inderes              Aiforia tecknar nytt kliniskt avtal i Frankrike - Inderes    Nantes universitetssjukhus kommer att driftsätta Aiforias programvara inom klinisk diagnostik. Värdet på det tvååriga avtalet kommunicerades inte i releasen.

Aiforia levererar sin bildanalysprogramvara till universitetssjukhuset i Nantes, Frankrike. Avtalet är litet, men stöder bolagets tillväxtutsikter och position på klinikmarknaden.                   Inderes              Aiforia signs new clinical account in France - Inderes    Nantes University Hospital will deploy Aiforia's software in clinical diagnostics. The value of the two-year agreement was not communicated in the release.

Aiforia is a company that has generated considerable discussion among investors. While some believe in its significant growth potential, the risks involved are also noteworthy. I definitely recommend reading this excellent and comprehensive analysis of the company.  Aiforia has become the market leader in clinical pathology image recognition, winning the majority of new contracts in the market in recent years. During the same period, the regulatory bottleneck that has been in the way of expanding the company’s product portfolio has opened, enabling expansion in existing customers and larger deal sizes in future tenders. Although the trade war that has started will have a potentially milder negative impact on the market, we expect Aiforia’s revenue growth to be on a strong footing in the near future. Supported by these drivers, we see the risk/reward of the stock at an attractive level. We revise our target price to EUR 4.2 (was EUR 4.4) and reiterate our Accumulate recommendation.                   Inderes              Aiforia Extensive Report: Track open for market takeover - Inderes    Aiforia has become the market leader in clinical pathology image recognition, winning the majority of new contracts in the market in recent years.

Det strategiska partnerskapet integrerar Aiforias bildigenkänningsmodeller i Techcytes digitala plattform för patologilaboratorier, med start från bröstcanceranalysen. De kombinerade lösningarna underlättar laboratoriernas övergång och minskar beroendet av enskilda leverantörer. Även om Aiforias roll kan försvagas möjliggör det en snabbare ökning av marknadsandelar och bättre kassaflöden för att minska investeringsbehoven. Partnerskapet främjar dessutom strategisk utveckling.  Här är analytikernas intressanta kommentarer i frågan:                   Inderes              Aiforias partnerskap med Techcyte erbjuder ett alternativ till strukturen för...    Partnerskapet kommer i princip att främja marknadsbildningen och stödja den starka intäktstillväxt som vi förutspår för Aiforia, även om det finns nyanser i frågan.

Aiforia har ingått ett partnerskap med det kanadensiska företaget Quorum Technologies, som kommer att integrera Aiforias lösning och stödja försäljningen. Partnerskapen stöder Aiforias tillväxtstrategi och kundanskaffning, och denna nyhet påverkar inte företagets utsikter. Läs analytikernas tankar om denna nyhet:                   Inderes              Aiforia’s partner network expands to Canada - Inderes    New partnerships are naturally positive for Aiforia, as they reflect the attractiveness of the company's image analysis solutions in the digital pathology market and improve the prerequisites for winning new customers.

Aiforia har valts som partner av hälsomyndigheterna på Sardinien för kliniska patologiska bildlösningar. Samarbetet omfattar analys av biopsier för bröst- och prostatacancer. Avtalet på Sardinien är mindre än de tidigare avtalen med Veneto- och Lombardien, som har större befolkning och bredare tillämpningsområden. Här är analytikerns tankar:                   Inderes              Aiforia selected as partner for Sardinia’s regional health authority - Inderes    Aiforia announced that the Sardinian region health authorities in Italy have selected the company as their partner for image analysis for clinical diagnostics in pathology.

Aiforia har fått CE-certifikat enligt den nya EU-förordningen (IVDR) och har lanserat tre nya AI-modeller. Detta möjliggör expansion inom kliniska partnerskap och ökar storleken på nya avtal. Jag rekommenderar att läsa analytikerns kommentar.                    Inderes              Aiforia finally obtained CE certification under the new regulation  - Inderes    Aiforia's CE markings, along with the rest of the industry, have been stuck since the end of May 2022 due to the EU's regulatory change for medical devices (IVDD -> IVDR).

Aiforia Technologies

New partnerships are naturally positive for Aiforia, as they reflect the attractiveness of the company's image analysis solutions in the digital pathology market and improve the prerequisites for winning new customers. 

Translation: Original published in Finnish on 03/18/2025 at 10:23 am EET
The company today&#xa0;<a href="https://www.inderes.se/releases/aiforia-expands-its-global-reach-through-a-partnership-with-quorum-technologies-in-canada" target="_blank" rel="noopener">announced</a> a partnership with the Canadian Quorum Technologies. Based on the announcement, Quorum will act as an integrator in the implementation of Aiforia&#x2019;s solution and support sales.
The partner channel is important for the company, as building own direct sales in all markets would not, in our view, be practical or financially sensible as the market is forming rapidly. Utilizing integrators also allows Aiforia to ramp up more customers simultaneously.
New partnerships are naturally positive for Aiforia, as they reflect the attractiveness of the company&apos;s image analysis solutions in the digital pathology market and improve the prerequisites for winning new customers. Our estimates expect the company to successfully implement its growth strategy, including continuous customer wins and accelerating revenue growth, so the release does not affect our view of the company.

	2024	25e	26e
Omsättning	2,9	4,7	7,6
tillväxt-%	18,9 %	65,7 %	60,0 %
EBIT (adj.)	−12,2	−11,9	−12,0
EBIT-%	−427,8 %	−252,9 %	−158,1 %
EPS (adj.)	−0,41	−0,36	−0,36
Utdelning	0,00	0,00	0,00
Direktavkastning
P/E (just.)	-	-	-
EV/EBITDA	-	-	-

Aiforia Technologies

Key Estimate Figures10/03